Heart Disease and Erectile Dysfunction pp 179-194 | Cite as
Safety and Hemodynamic Effects of Sildenafil in Patients With Coronary Artery Disease
Chapter
Abstract
Erectile dysfunction (ED), defined as the persistent inability to attain and/or maintain penile erection sufficient for sexual performance, affects up to 30 million men in the United States (1). Many of these men also suffer from cardiovascular disease because many of the risk factors for ED are also established risk factors for coronary artery disease (CAD). These risk factors include older age, diabetes mellitus, hypertension, smoking, and dyslipidemia. It is also likely, but not proven, that oxidative stress resulting in endothelial dysfunction contributes to the pathogenesis of both diseases. The incidence of ED may also be exacerbated by cardiovascular illness, such as myocardial infarction (MI) and congestive heart failure (CHF), and by the treatment for CAD, including antihypertensive/antianginal medications such as β-blockers.
Keywords
Erectile Dysfunction Coronary Flow Reserve Coronary Blood Flow Adverse Cardiovascular Event Severe Coronary Artery Disease
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Preview
Unable to display preview. Download preview PDF.
References
- 1.NIH Consensus Development Panel on Impotence. NIH Consensus Conference: impotence. JAMA. 1993; 270: 83–90.CrossRefGoogle Scholar
- 2.Goldstein I, Lue TF, Padma-Nathan H, et al. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med 1998; 338: 1397–1404.PubMedCrossRefGoogle Scholar
- 3.Viagra (sildenafil citrate) [revised package insert]. New York, NY: Pfizer; June, 1999.Google Scholar
- 4.Zusman RM, Morales A, Glasser DB, et al. Overall cardiovascular profile of sildenafil citrate. Am J Cardiol. 1999; 83 (Suppl 5A): 35C–44C.PubMedCrossRefGoogle Scholar
- 5.Kloner RA. Cardiovascular risk and sildenafil. Am J Cardiol 2000; 86 (Suppl): 57F–61F.PubMedCrossRefGoogle Scholar
- 6.Morales A, Gingell C, Collins M, et al. Clinical safety of oral sildenafil citrate (Viagra) in the treatment of erectile dysfunction. Int J Impotence Res 1998; 10: 69–74.CrossRefGoogle Scholar
- 7.Conti RC, Pepine C, Sweeney M. Efficacy and safety of sildenafil citrate in the treatment of erectile dysfunction in patients with ischemic heart disease. Am J Cardiol 1999; 83 (Suppl): 29C–34C.PubMedCrossRefGoogle Scholar
- 8.Morales A, Gingell C, Collins M, et al. Clinical safety of oral sildenafil citrate (Viagra) in the treatment of erectile dysfunction. Int J Impotence Res 1998; 10: 69–74.CrossRefGoogle Scholar
- 9.Pfizer data on file, unpublished.Google Scholar
- 10.Shakir SA, Wilton LV, Boshier A, et al. Cardiovascular events in users of sildenafil: results from first phase of prescription event monitoring in England. Br Med J 2001; 322: 651–652.CrossRefGoogle Scholar
- 11.Wallis RM, Corbin JD, Francis SH, et al. Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. Am J Cardiol 1999; 83: 3C–12C.PubMedCrossRefGoogle Scholar
- 12.Jackson G, Benjamin N, Jackson N, et al. Effects of sildenafil citrate on human hemodynamics. Am J Cardiol 1999; 83 (Suppl): 13C–20C.PubMedCrossRefGoogle Scholar
- 13.Herrmann HC, Chang G, Klugherz BD, et al. Hemodynamic effects of sildenafil in men with severe coronary artery disease. N Engl J Med 2000; 342: 1622–1626.PubMedCrossRefGoogle Scholar
- 14.Webb DJ, Freestone S, Allen MJ, et al. Sildenafil citrate and blood-pressurelowering drugs: results of drug interaction studies with an organic nitrate and a calcium antagonist. Am J Cardiol 1999; 83 (Suppl): 21C–28C.PubMedCrossRefGoogle Scholar
- 15.Kloner RA, Brown M, Prisant LM, et al. Effects of sildenafil in patients with erectile dysfunction taking antihypertensive therapy. Am J Hypertens 2001; 14: 70–73.PubMedCrossRefGoogle Scholar
- 16.Arruda-Olson AM, Mahoney DW, Nehra A, et al. Cardiovascular effects of sildenafil during exercise in men with known or probable coronary artery disease. JAMA 2002; 287: 719–725.PubMedCrossRefGoogle Scholar
- 17.Fox KM, Thadani U, Ma PTS, et al. Time to onset of limiting angina during treadmill exercise in men with erectile dysfunction and stable chronic angina: effect of sildenafil citrate (abst). Circulation 2001; 104: II–601.Google Scholar
- 18.Jaarsma T, Dracup K, Walden J, et al. Sexual function in patients with advanced heart failure. Heart Lung 1996; 25: 262–270.PubMedCrossRefGoogle Scholar
- 19.Katz SD, Balidemaj K, Homma S, et al. Acute type 5 phosphodiesterase inhibition with sildenafil citrate enhances flow-mediated vasodilatation in patients with chronic heart failure. J Am Coll Cardiol 2000; 36: 845–851.PubMedCrossRefGoogle Scholar
- 20.Bocchi EA, Guimaraes G, Mocelin A, et al. Sildenafil effects on exercise, neurohormonal activation, and erectile dysfunction in congestive heart failure. Circulation 2002; 106: 1097–1103.PubMedCrossRefGoogle Scholar
- 21.Zusman R, Morales A, Glasser D, et al. Overall cardiovascular profile of sildenafil citrate. Am J Cardiol 1999; 83: 35C–44C.PubMedCrossRefGoogle Scholar
- 22.Geelen P, Benoit D, Rail J, et al. Sildenafil (Viagra) prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current. Circulation 2000; 102: 275–277.PubMedCrossRefGoogle Scholar
- 23.Piccirillo G, Nocco M, Lionetti M, et al. Effects of sildenafil citrate (Viagra) on cardiac repolarization and on autonomic control in subjects with chronic heart failure. Am Heart J 2002; 143: 703–710.PubMedCrossRefGoogle Scholar
- 24.Muller JE. Triggering of cardiac events by sexual activity: findings from a case-crossover analysis. Am J Caridiol 2000; 86 (Suppl): 14F–18F.CrossRefGoogle Scholar
- 25.Drory Y, Shapira I, Fisman EZ, et al. Myocardial ischemia during sexual activity in patients with coronary artery disease. Am J Cardiol 1995; 75: 835–837.PubMedCrossRefGoogle Scholar
Copyright information
© Humana Press Inc., Totowa, NJ 2004